Published in Schizophr Bull on March 31, 2014
Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia | NCT03788759
Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology? Schizophr Res (2014) 1.06
The promise of biological markers for treatment response in first-episode psychosis: a systematic review. Schizophr Bull (2015) 1.03
How can studies of resting-state functional connectivity help us understand psychosis as a disorder of brain development? Curr Opin Neurobiol (2014) 0.85
The proteome of schizophrenia. NPJ Schizophr (2015) 0.79
Oxidative/Nitrosative stress in psychiatric disorders: are we there yet? Schizophr Bull (2014) 0.78
Glutathione Deficit Affects the Integrity and Function of the Fimbria/Fornix and Anterior Commissure in Mice: Relevance for Schizophrenia. Int J Neuropsychopharmacol (2015) 0.76
Differentiation of oligodendrocyte precursors is impaired in the prefrontal cortex in schizophrenia. Schizophr Res (2015) 0.76
Neuronal copper homeostasis susceptibility by genetic defects in dysbindin, a schizophrenia susceptibility factor. Hum Mol Genet (2015) 0.76
Lipid profiles in schizophrenia associated with clinical traits: a five year follow-up study. BMC Psychiatry (2016) 0.75
Human dermal fibroblasts in psychiatry research. Neuroscience (2016) 0.75
Redox Dysregulation in Schizophrenia Revealed by in vivo NAD+/NADH Measurement. Schizophr Bull (2016) 0.75
Increased extracellular clusterin in the prefrontal cortex in schizophrenia. Schizophr Res (2015) 0.75
Implication of the glutamate-cystine antiporter xCT in schizophrenia cases linked to impaired GSH synthesis. NPJ Schizophr (2017) 0.75
Statistical significance for genomewide studies. Proc Natl Acad Sci U S A (2003) 88.64
Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry (1991) 5.36
Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry (2005) 5.17
Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry (2009) 4.44
Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry (2004) 3.90
Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol (2004) 3.83
Chemical and molecular regulation of enzymes that detoxify carcinogens. Proc Natl Acad Sci U S A (1993) 3.24
Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry (1991) 3.21
Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol Pathol (2009) 2.16
Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol (1999) 2.09
Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol (2009) 2.09
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci (2000) 2.06
Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci U S A (2007) 1.80
Emotional reactivity to daily life stress in psychosis and affective disorder: an experience sampling study. Acta Psychiatr Scand (2003) 1.79
Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry (2007) 1.78
Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol (1996) 1.68
Altered glutathione redox state in schizophrenia. Dis Markers (2006) 1.67
An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry (1995) 1.67
Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res (1998) 1.63
Role of oxidants and antioxidants in the induction of AP-1, NF-kappaB, and glutathione S-transferase gene expression. J Biol Chem (1996) 1.61
Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biol Psychiatry (2011) 1.60
Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol (2010) 1.56
Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet (2006) 1.50
Perineuronal nets protect fast-spiking interneurons against oxidative stress. Proc Natl Acad Sci U S A (2013) 1.45
Diagnostic interview for genetic studies (DIGS): inter-rater and test-retest reliability of the French version. Eur Arch Psychiatry Clin Neurosci (1999) 1.45
Modulation and block of ion channels: a new biology of polyamines. Cell Signal (1997) 1.40
Potential metabolite markers of schizophrenia. Mol Psychiatry (2011) 1.35
Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res (2000) 1.34
Early-life insults impair parvalbumin interneurons via oxidative stress: reversal by N-acetylcysteine. Biol Psychiatry (2012) 1.26
The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev (2000) 1.20
Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res (2002) 1.16
Genome-wide profiling of multiple histone methylations in olfactory cells: further implications for cellular susceptibility to oxidative stress in schizophrenia. Mol Psychiatry (2012) 1.14
Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr Bull (2004) 1.11
An investigation into the population abundance distribution of mRNAs, proteins, and metabolites in biological systems. Bioinformatics (2009) 1.10
Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res (2003) 1.10
Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res (2005) 1.07
Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res (2012) 1.05
The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease. J Bioenerg Biomembr (2009) 1.05
Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.04
Psychosocial stress is associated with in vivo dopamine release in human ventromedial prefrontal cortex: a positron emission tomography study using [¹⁸F]fallypride. Neuroimage (2011) 1.04
Primary skin fibroblasts as a model of Parkinson's disease. Mol Neurobiol (2012) 1.01
Subtle fluctuations in psychotic phenomena as functional states of abnormal dopamine reactivity in individuals at risk. Biol Psychiatry (2005) 1.00
A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res (1994) 0.99
Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med (2011) 0.98
Nitric oxide signaling and nitrosative stress in neurons: role for S-nitrosylation. Antioxid Redox Signal (2011) 0.97
Redox dysregulation in the pathophysiology of schizophrenia and bipolar disorder: insights from animal models. Antioxid Redox Signal (2012) 0.95
Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study. Schizophr Res (1994) 0.94
Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia. Antioxid Redox Signal (2010) 0.93
A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia. Schizophr Res (2012) 0.93
Impaired plasmalogens in patients with schizophrenia. Psychiatry Res (2012) 0.93
Intracellular polyamines enhance astrocytic coupling. Neuroreport (2012) 0.93
Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med (2012) 0.91
Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry (2012) 0.91
Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease. J Neural Transm Park Dis Dement Sect (1994) 0.90
A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci (2010) 0.89
Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res (2012) 0.88
Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients. Transl Psychiatry (2012) 0.86
Putrescine produces antidepressant-like effects in the forced swimming test and in the tail suspension test in mice. Prog Neuropsychopharmacol Biol Psychiatry (2006) 0.86
Increased stress reactivity: a mechanism specifically associated with the positive symptoms of psychotic disorder. Psychol Med (2012) 0.85
Treatment and early intervention in psychosis program (TIPP-Lausanne): Implementation of an early intervention programme for psychosis in Switzerland. Early Interv Psychiatry (2013) 0.84
Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations. Prog Neuropsychopharmacol Biol Psychiatry (2006) 0.84
Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res (1995) 0.84
A 1H-decoupled 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls. Biol Psychiatry (1999) 0.83
Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophr Res (1994) 0.83
Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukot Essent Fatty Acids (1996) 0.83
Detection of respiratory chain defects in cultivated skin fibroblasts and skeletal muscle of patients with Parkinson's disease. Ann N Y Acad Sci (1999) 0.82
Is agmatine an endogenous anxiolytic/antidepressant agent? Ann N Y Acad Sci (2003) 0.81
Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test. Eur J Pharmacol (2007) 0.80
Lateralized abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorus-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia. Psychiatry Res (1995) 0.80
Erythrocyte membrane phospholipids in psychotic patients. Psychiatry Res (1993) 0.79
The role of prostaglandin H synthase-mediated metabolism in the induction of oxidative DNA damage by BHA metabolites. Carcinogenesis (1993) 0.79
Decreased adhesiveness and altered cellular distribution of fibronectin in fibroblasts from schizophrenic patients. Psychiatry Res (1994) 0.78
The brain dopaminergic system. Pharmacological, behavioural and electrophysiological studies. Dan Med Bull (1995) 0.78
Multiple regression analysis of relationship between frontal lobe phosphorus metabolism and clinical symptoms in patients with schizophrenia. Psychiatry Res (1997) 0.77
31P magnetic resonance spectroscopy studies in schizophrenia. Prostaglandins Leukot Essent Fatty Acids (1996) 0.77
Developing psychosis and its risk states through the lens of schizotypy. Schizophr Bull (2014) 0.88